Domenico Bonaduce
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Domenico Bonaduce has a total of 479 co-authors. Here are the top co-authors by number of shared publications:
- Mario Petretta
Department of Advanced Biomedical Sciences, University of Naples Federico II
56 shared publications - Pasquale Abete
Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy
25 shared publications - Alberto Cuocolo
Department of Advanced Biomedical Sciences, University of Naples “Federico II”, Naples, Italy
19 shared publications M Petretta
19 shared publications- David Della-Morte
Section of Food Chemistry, Clinical Nutrition and Pharmaceutical Science, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
14 shared publications - Franco Rengo
Istituto Scientifico di Campoli/Telese, Fondazione Salvatore Maugeri, IRCCS, Benevento, Italy
14 shared publications
Latest Publications
- Open Access
- 22 June 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (12) , 4430
Pulmonary Hypertension Phenotypes in Systemic Sclerosis: The Right Diagnosis for the Right Treatment
Systemic sclerosis is an auto-immune disease characterized by skin involvement that often affects multiple organ systems. Pulmonary hypertension is a common finding that can significantly impact prognosis. Molecular pathophysiological mechanisms underlying pulmonary hypertension in systemic sclerosis can be extremely heterogeneous, leading to distinct clinical phenotypes. In addition, different causes of pulmonary hypertension may overlap within the same patient. Since pulmonary hypertension treatment is very different for each phenotype, it is fundamental to perform an adequate diagnostic work-up to properly and promptly identify the prevalent mechanism underlying pulmonary hypertension in order to start the right therapies. When pulmonary hypertension is caused by a primary vasculopathy of the small pulmonary arteries, treatment with pulmonary vasodilators, often in an initial double-combination regimen, is indicated, aimed at reducing the mortality risk profile. In this review, we describe the different clinical phenotypes of pulmonary hypertension in the scleroderma population and discuss the utility of clinical tools to identify the presence of pulmonary vascular disease. Furthermore, we focus on systemic sclerosis-associated pulmonary arterial hypertension, highlighting the advances in the knowledge of right ventricular dysfunction in this setting and the latest updates in terms of treatment with pulmonary vasodilator drugs.
- 22 June 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (12) , 4430
Open AccessPulmonary Hypertension Phenotypes in Systemic Sclerosis: The Right Diagnosis for the Right Treatment
Systemic sclerosis is an auto-immune disease characterized by skin involvement that often affects multiple organ systems. Pulmonary hypertension is a common finding that can significantly impact prognosis. Molecular pathophysiological mechanisms underlying pulmonary hypertension in systemic sclerosis can be extremely heterogeneous, leading to distinct clinical phenotypes. In addition, different causes of pulmonary hypertension may overlap within the same patient. Since pulmonary hypertension treatment is very different for each phenotype, it is fundamental to perform an adequate diagnostic work-up to properly and promptly identify the prevalent mechanism underlying pulmonary hypertension in order to start the right therapies. When pulmonary hypertension is caused by a primary vasculopathy of the small pulmonary arteries, treatment with pulmonary vasodilators, often in an initial double-combination regimen, is indicated, aimed at reducing the mortality risk profile. In this review, we describe the different clinical phenotypes of pulmonary hypertension in the scleroderma population and discuss the utility of clinical tools to identify the presence of pulmonary vascular disease. Furthermore, we focus on systemic sclerosis-associated pulmonary arterial hypertension, highlighting the advances in the knowledge of right ventricular dysfunction in this setting and the latest updates in terms of treatment with pulmonary vasodilator drugs.
- Top Cited PapersOpen Access
Sarcopenia and Heart Failure
Modifications of lean mass are a frequent critical determinant in the pathophysiology and progression of heart failure (HF). Sarcopenia may be considered one of the most important causes of low physical performance and reduced cardiorespiratory fitness in older patients with HF. Sarcopenia is frequently misdiagnosed as cachexia. However, muscle wasting in HF has different pathogenetic features in sarcopenic and cachectic conditions. HF may induce sarcopenia through common pathogenetic pathways such as hormonal changes, malnutrition, and physical inactivity; mechanisms that influence each other. In the opposite way, sarcopenia may favor HF development by different mechanisms, including pathological ergoreflex. Paradoxically, sarcopenia is not associated with a sarcopenic cardiac muscle, but the cardiac muscle shows a hypertrophy which seems to be “not-functional.” First-line agents for the treatment of HF, physical activity and nutritional interventions, may offer a therapeutic advantage in sarcopenic patients irrespective of HF. Thus, sarcopenia is highly prevalent in patients with HF, contributing to its poor prognosis, and both conditions could benefit from common treatment strategies based on pharmacological, physical activity, and nutritional approaches.
Top Cited PapersOpen AccessSarcopenia and Heart Failure
Modifications of lean mass are a frequent critical determinant in the pathophysiology and progression of heart failure (HF). Sarcopenia may be considered one of the most important causes of low physical performance and reduced cardiorespiratory fitness in older patients with HF. Sarcopenia is frequently misdiagnosed as cachexia. However, muscle wasting in HF has different pathogenetic features in sarcopenic and cachectic conditions. HF may induce sarcopenia through common pathogenetic pathways such as hormonal changes, malnutrition, and physical inactivity; mechanisms that influence each other. In the opposite way, sarcopenia may favor HF development by different mechanisms, including pathological ergoreflex. Paradoxically, sarcopenia is not associated with a sarcopenic cardiac muscle, but the cardiac muscle shows a hypertrophy which seems to be “not-functional.” First-line agents for the treatment of HF, physical activity and nutritional interventions, may offer a therapeutic advantage in sarcopenic patients irrespective of HF. Thus, sarcopenia is highly prevalent in patients with HF, contributing to its poor prognosis, and both conditions could benefit from common treatment strategies based on pharmacological, physical activity, and nutritional approaches.
- Open Access
- 30 April 2019
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (9) , 2154
Inflammatory, Serological and Vascular Determinants of Cardiovascular Disease in Systemic Lupus Erythematosus Patients
Background and aim: Systemic lupus erythematosus (SLE) is associated with increased risk of cardiovascular disease (CVD). Among many mechanisms, accelerated atherosclerosis, endothelial dysfunction, and hypercoagulability play a main role. Here, we investigate whether inflammatory, serological and clinical markers of SLE determine and correlate with arterial stiffness in SLE patients. Materials and methods: Routine blood samples, inflammatory mediators, specific antibodies, and 24 h proteinuria were measured in 43 SLE patients and 43 age and sex-matched controls using routine laboratory assays. We also assessed arterial stiffness by measuring radial artery applanation tonometry-derived augmentation index (AI), normalized AI (AIx@75), aortic pulse pressure, central systolic, diastolic and peripheral blood pressure. Results: SLE patients showed a significantly greater arterial stiffness vs. controls, as demonstrated by the significantly higher AIx@75 and aortic pulse pressure. Interestingly, regression analysis showed that age, systolic pulse pressure, inflammatory markers (erythrocyte sedimentation rate and C-reactive protein), daily dose of glucocorticoids, and cumulative organ damage positively correlated with arterial stiffness. Conclusions: SLE patients show increased arterial stiffness which correlates with markers of inflammation, that is involved in early alterations in arterial walls. Applanation tonometry can be used to screen SLE patients for subclinical vascular damage to implement prevention strategies for CVD.
- 30 April 2019
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (9) , 2154
Open AccessInflammatory, Serological and Vascular Determinants of Cardiovascular Disease in Systemic Lupus Erythematosus Patients
Background and aim: Systemic lupus erythematosus (SLE) is associated with increased risk of cardiovascular disease (CVD). Among many mechanisms, accelerated atherosclerosis, endothelial dysfunction, and hypercoagulability play a main role. Here, we investigate whether inflammatory, serological and clinical markers of SLE determine and correlate with arterial stiffness in SLE patients. Materials and methods: Routine blood samples, inflammatory mediators, specific antibodies, and 24 h proteinuria were measured in 43 SLE patients and 43 age and sex-matched controls using routine laboratory assays. We also assessed arterial stiffness by measuring radial artery applanation tonometry-derived augmentation index (AI), normalized AI (AIx@75), aortic pulse pressure, central systolic, diastolic and peripheral blood pressure. Results: SLE patients showed a significantly greater arterial stiffness vs. controls, as demonstrated by the significantly higher AIx@75 and aortic pulse pressure. Interestingly, regression analysis showed that age, systolic pulse pressure, inflammatory markers (erythrocyte sedimentation rate and C-reactive protein), daily dose of glucocorticoids, and cumulative organ damage positively correlated with arterial stiffness. Conclusions: SLE patients show increased arterial stiffness which correlates with markers of inflammation, that is involved in early alterations in arterial walls. Applanation tonometry can be used to screen SLE patients for subclinical vascular damage to implement prevention strategies for CVD.
- 21 February 2018
- Published by Springer Nature in Aging Clinical and Experimental Research
- Vol. 30 (7) , 703-712
Acute care hospital at different levels of intensity: the role of Geriatrician
The traditional model of care is based on “disease-centered” management that requires the organization of the hospital in specialized wards, to which the patient is assigned for the main disease. The growing need to optimize economical and human resources and to promote a global approach to the patient has led to the setting up of the intensity of care model. It is a health system based on a “patient-centered” approach, where the hospital is organized in departments dedicated to patients with homogenous needs of care. In Italy, intensity of care model is currently being tested in the hospital organization, where three levels of intensity are proposed: low, medium and high. The purpose of the following review is to describe the role and importance of the Geriatrician in each of these care settings and to highlight the contradiction of a National Health System which promotes the geriatric approach to all types of patients, but does not invest in the formation and integration of the figure of the Geriatrician in clinical practice, condemning it to marginalization or even extinction.
- 21 February 2018
- Published by Springer Nature in Aging Clinical and Experimental Research
- Vol. 30 (7) , 703-712
Acute care hospital at different levels of intensity: the role of Geriatrician
The traditional model of care is based on “disease-centered” management that requires the organization of the hospital in specialized wards, to which the patient is assigned for the main disease. The growing need to optimize economical and human resources and to promote a global approach to the patient has led to the setting up of the intensity of care model. It is a health system based on a “patient-centered” approach, where the hospital is organized in departments dedicated to patients with homogenous needs of care. In Italy, intensity of care model is currently being tested in the hospital organization, where three levels of intensity are proposed: low, medium and high. The purpose of the following review is to describe the role and importance of the Geriatrician in each of these care settings and to highlight the contradiction of a National Health System which promotes the geriatric approach to all types of patients, but does not invest in the formation and integration of the figure of the Geriatrician in clinical practice, condemning it to marginalization or even extinction.
- 13 February 2018
- Published by Wiley in Nutrition in Clinical Practice
- Vol. 33 (6) , 879-886
Risk of Malnutrition Evaluated by Mini Nutritional Assessment and Sarcopenia in Noninstitutionalized Elderly People
Background: Malnutrition indices and muscle mass and strength in the elderly are poorly investigated. Moreover, malnutrition seems to be 1 of the more important factors in the cause of sarcopenia. The presence of sarcopenia and its relationship with malnutrition indices were studied in noninstitutionalized elderly people who underwent Comprehensive Geriatric Assessment (CGA).Methods: A total of 473 elderly subjects (mean age, 80.9 ± 6.6 years) admitted to CGA were studied. Malnutrition risk was evaluated with Mini Nutritional Assessment (MNA) score, whereas muscle mass and muscle strength were evaluated by bioimpedentiometry and hand grip, respectively. Sarcopenia was assessed as indicated in the European Working Group on Sarcopenia in Older People (EWGSOP) consensus.Results: Overall prevalence of sarcopenia was 13.1%, and it increased from 6.1% to 31.4% as MNA decreased (P < .001). MNA score was lower in elderly subjects with sarcopenia (15.4 ± 4.2) than without sarcopenia (22.0 ± 4.0) (P = .024). Linear regression analysis showed that MNA score is linearly related both with muscle mass (r = 0.72; P < .001) and strength (r = 0.42; P < .001). Multivariate analysis, adjusted for several confounding variables including comorbidity and disability, confirmed these results.Conclusions: MNA score is low in noninstitutionalized elderly subjects with sarcopenia, and it is linearly related to muscle mass and muscle strength. These data indicate that MNA score, when evaluated with muscle mass and strength, may recognize elderly subjects with sarcopenia.
- 13 February 2018
- Published by Wiley in Nutrition in Clinical Practice
- Vol. 33 (6) , 879-886
Risk of Malnutrition Evaluated by Mini Nutritional Assessment and Sarcopenia in Noninstitutionalized Elderly People
Background: Malnutrition indices and muscle mass and strength in the elderly are poorly investigated. Moreover, malnutrition seems to be 1 of the more important factors in the cause of sarcopenia. The presence of sarcopenia and its relationship with malnutrition indices were studied in noninstitutionalized elderly people who underwent Comprehensive Geriatric Assessment (CGA).Methods: A total of 473 elderly subjects (mean age, 80.9 ± 6.6 years) admitted to CGA were studied. Malnutrition risk was evaluated with Mini Nutritional Assessment (MNA) score, whereas muscle mass and muscle strength were evaluated by bioimpedentiometry and hand grip, respectively. Sarcopenia was assessed as indicated in the European Working Group on Sarcopenia in Older People (EWGSOP) consensus.Results: Overall prevalence of sarcopenia was 13.1%, and it increased from 6.1% to 31.4% as MNA decreased (P < .001). MNA score was lower in elderly subjects with sarcopenia (15.4 ± 4.2) than without sarcopenia (22.0 ± 4.0) (P = .024). Linear regression analysis showed that MNA score is linearly related both with muscle mass (r = 0.72; P < .001) and strength (r = 0.42; P < .001). Multivariate analysis, adjusted for several confounding variables including comorbidity and disability, confirmed these results.Conclusions: MNA score is low in noninstitutionalized elderly subjects with sarcopenia, and it is linearly related to muscle mass and muscle strength. These data indicate that MNA score, when evaluated with muscle mass and strength, may recognize elderly subjects with sarcopenia.
- Open Access
- 11 December 2017
- Published by Wiley in Stem Cells International
- Vol. 2017, 1-12
Nanotechnology-Based Cardiac Targeting and Direct Cardiac Reprogramming: The Betrothed
Cardiovascular diseases represent the first cause of morbidity in Western countries, and chronic heart failure features a significant health care burden in developed countries. Efforts in the attempt of finding new possible strategies for the treatment of CHF yielded several approaches based on the use of stem cells. The discovery of direct cardiac reprogramming has unveiled a new approach to heart regeneration, allowing, at least in principle, the conversion of one differentiated cell type into another without proceeding through a pluripotent intermediate. First developed for cancer treatment, nanotechnology-based approaches have opened new perspectives in many fields of medical research, including cardiovascular research. Nanotechnology could allow the delivery of molecules with specific biological activity at a sustained and controlled rate in heart tissue, in a cell-specific manner. Potentially, all the mediators and structural molecules involved in the fibrotic process could be selectively targeted by nanocarriers, but to date, only few experiences have been made in cardiac research. This review highlights the most prominent concepts that characterize both the field of cardiac reprogramming and a nanomedicine-based approach to cardiovascular diseases, hypothesizing a possible synergy between these two very promising fields of research in the treatment of heart failure.
- 11 December 2017
- Published by Wiley in Stem Cells International
- Vol. 2017, 1-12
Open AccessNanotechnology-Based Cardiac Targeting and Direct Cardiac Reprogramming: The Betrothed
Cardiovascular diseases represent the first cause of morbidity in Western countries, and chronic heart failure features a significant health care burden in developed countries. Efforts in the attempt of finding new possible strategies for the treatment of CHF yielded several approaches based on the use of stem cells. The discovery of direct cardiac reprogramming has unveiled a new approach to heart regeneration, allowing, at least in principle, the conversion of one differentiated cell type into another without proceeding through a pluripotent intermediate. First developed for cancer treatment, nanotechnology-based approaches have opened new perspectives in many fields of medical research, including cardiovascular research. Nanotechnology could allow the delivery of molecules with specific biological activity at a sustained and controlled rate in heart tissue, in a cell-specific manner. Potentially, all the mediators and structural molecules involved in the fibrotic process could be selectively targeted by nanocarriers, but to date, only few experiences have been made in cardiac research. This review highlights the most prominent concepts that characterize both the field of cardiac reprogramming and a nanomedicine-based approach to cardiovascular diseases, hypothesizing a possible synergy between these two very promising fields of research in the treatment of heart failure.
- 14 November 2017
- Published by Springer Nature in Aging Clinical and Experimental Research
- Vol. 30 (8) , 1011-1013
Thromboembolic and bleeding risk management in elderly patients: a case report
- 14 November 2017
- Published by Springer Nature in Aging Clinical and Experimental Research
- Vol. 30 (8) , 1011-1013
Thromboembolic and bleeding risk management in elderly patients: a case report
- 11 August 2017
- Published by S. Karger AG in American Journal of Noninvasive Cardiology
- Vol. 5, 98-102
Doppler Echocardiographie Evaluation of Three Models of Prosthetic Valves in the Aortic Position
Characteristics of three models of normally functioning prosthetic valves in the aortic position were compared using Doppler échocardiographie technique. Maximal aortic velocity (V(max)) was recorded in 68 patients in whom Carpentier-Edwards (n = 29), Hancock (n = 25), and St. Jude (n = 14) prosthetic valves had been implanted in the aortic position. Mean V(max) values were 2.55 ± 0.55 m/s for Carpentier-Edwards, 2.49 ± 0.74 m/s for Hancock and 2.74 ± 0.31 m/s for St. Jude. A considerable variation in V(max) values was also observed according to valve model and size. The highest V(max) values were recorded in patients with small Hancock valves. Moreover, only Hancock valves presented significantly different V(max) values between larger and smaller sizes (p < 0.001). No correlation between V(max) and postoperative interval or patient’s age was found in any valve model. This study demonstrates that Hancock valve implantation in the aortic position does not seem preferable if a small prosthesis is needed; the wide-ranging intersubject differences in V(max) values need to be considered in evaluating prosthetic valve function utilizing Doppler techniques.
- 11 August 2017
- Published by S. Karger AG in American Journal of Noninvasive Cardiology
- Vol. 5, 98-102
Doppler Echocardiographie Evaluation of Three Models of Prosthetic Valves in the Aortic Position
Characteristics of three models of normally functioning prosthetic valves in the aortic position were compared using Doppler échocardiographie technique. Maximal aortic velocity (V(max)) was recorded in 68 patients in whom Carpentier-Edwards (n = 29), Hancock (n = 25), and St. Jude (n = 14) prosthetic valves had been implanted in the aortic position. Mean V(max) values were 2.55 ± 0.55 m/s for Carpentier-Edwards, 2.49 ± 0.74 m/s for Hancock and 2.74 ± 0.31 m/s for St. Jude. A considerable variation in V(max) values was also observed according to valve model and size. The highest V(max) values were recorded in patients with small Hancock valves. Moreover, only Hancock valves presented significantly different V(max) values between larger and smaller sizes (p < 0.001). No correlation between V(max) and postoperative interval or patient’s age was found in any valve model. This study demonstrates that Hancock valve implantation in the aortic position does not seem preferable if a small prosthesis is needed; the wide-ranging intersubject differences in V(max) values need to be considered in evaluating prosthetic valve function utilizing Doppler techniques.
- 11 August 2017
- Published by S. Karger AG in American Journal of Noninvasive Cardiology
- Vol. 3, 74-79
Influence of Normalization Techniques upon Two-Dimensional Doppler-Derived Peak Filling Rate: Comparison with Radionuclide Angiography
In this study we evaluated if two-dimensional Doppler (2DD)-derived peak filling rate (PFR) normalized to stroke volume (SV) could provide a useful index of diastolic function that can be compared to PFR obtained with radionuclide angiography (RNA). Forty-five patients, 22 with clinical evidence of healed myocardial infarction (MI) and 23 of primary hypertension underwent 2DD and RNA study within 24 h. 2DD- and RNA-derived PFR were normalized to end-diastolic volume (PFR-EDV) and to SV (PFR-SV): PFR determined by 2DD correlated with RNA in the total study population (r = 0.45; p < 0.01), in MI (r = 0.51; p < 0.01) and in hypertensive (H) patients (r = 0.43; p < 0.05) when both were normalized to SV; however, when normalized to end-diastolic volume, 2DD-derived PFR also correlated with RNA in the total study population (r = 0.36; p < 0.05) and in H patients (r = 0.48; p < 0.05) but not in MI patients (r = 0.37; NS). Furthermore, PFR-SV and PFR-EDV measured by RNA closely correlated in the total study population (r = 0.81; p < 0.001), in MI (r = 0.86; p < 0.001), and in H patients (r = 0.86; p < 0.001), while, when assessed by 2DD, the r values of the correlations between the same parameters in the total study population (r = 0.44; p < 0.01), in MI (r = 0.47; p < 0.05) and in H patients (r = 0.43; p < 0.05) were lower. Thus, 2DD-derived PFR normalized to SV more than to EDV might be useful in assessing left ventricular diastolic filling abnormalities in cardiac patients, in particular in those with healed MI.
- 11 August 2017
- Published by S. Karger AG in American Journal of Noninvasive Cardiology
- Vol. 3, 74-79
Influence of Normalization Techniques upon Two-Dimensional Doppler-Derived Peak Filling Rate: Comparison with Radionuclide Angiography
In this study we evaluated if two-dimensional Doppler (2DD)-derived peak filling rate (PFR) normalized to stroke volume (SV) could provide a useful index of diastolic function that can be compared to PFR obtained with radionuclide angiography (RNA). Forty-five patients, 22 with clinical evidence of healed myocardial infarction (MI) and 23 of primary hypertension underwent 2DD and RNA study within 24 h. 2DD- and RNA-derived PFR were normalized to end-diastolic volume (PFR-EDV) and to SV (PFR-SV): PFR determined by 2DD correlated with RNA in the total study population (r = 0.45; p < 0.01), in MI (r = 0.51; p < 0.01) and in hypertensive (H) patients (r = 0.43; p < 0.05) when both were normalized to SV; however, when normalized to end-diastolic volume, 2DD-derived PFR also correlated with RNA in the total study population (r = 0.36; p < 0.05) and in H patients (r = 0.48; p < 0.05) but not in MI patients (r = 0.37; NS). Furthermore, PFR-SV and PFR-EDV measured by RNA closely correlated in the total study population (r = 0.81; p < 0.001), in MI (r = 0.86; p < 0.001), and in H patients (r = 0.86; p < 0.001), while, when assessed by 2DD, the r values of the correlations between the same parameters in the total study population (r = 0.44; p < 0.01), in MI (r = 0.47; p < 0.05) and in H patients (r = 0.43; p < 0.05) were lower. Thus, 2DD-derived PFR normalized to SV more than to EDV might be useful in assessing left ventricular diastolic filling abnormalities in cardiac patients, in particular in those with healed MI.
- 9 August 2017
- Published by Springer Nature in Aging Clinical and Experimental Research
- Vol. 30 (6) , 547-554
The reverse metabolic syndrome in the elderly: Is it a “catabolic” syndrome?
Traditional risk factors of cardiovascular death in the general population, including body mass index (BMI), serum cholesterol, and blood pressure are also found to relate to outcomes in the geriatric population, but in a differing direction. A higher body mass index, hypercholesterolemia and hypertension are not harmful but even permit better survival at advancing age. This phenomenon is called “reverse epidemiology” or “risk factor paradox” and is also detected in a variety of chronic disease states such as chronic heart failure. Accordingly, a low BMI, blood pressure and cholesterol values are associated with a worse prognosis. Several possible causes are hypothesized to explain this elderly paradox, but this phenomenon remains controversial and its underlying reasons are poorly understood. The aim of this review is to recognize the factors behind this intriguing phenomenon and analyse the consequences that it can bring in the management of the cardiovascular therapy in elderly patient. Finally, a new phenotype identified as “catabolic syndrome” has been postulated.
- 9 August 2017
- Published by Springer Nature in Aging Clinical and Experimental Research
- Vol. 30 (6) , 547-554
The reverse metabolic syndrome in the elderly: Is it a “catabolic” syndrome?
Traditional risk factors of cardiovascular death in the general population, including body mass index (BMI), serum cholesterol, and blood pressure are also found to relate to outcomes in the geriatric population, but in a differing direction. A higher body mass index, hypercholesterolemia and hypertension are not harmful but even permit better survival at advancing age. This phenomenon is called “reverse epidemiology” or “risk factor paradox” and is also detected in a variety of chronic disease states such as chronic heart failure. Accordingly, a low BMI, blood pressure and cholesterol values are associated with a worse prognosis. Several possible causes are hypothesized to explain this elderly paradox, but this phenomenon remains controversial and its underlying reasons are poorly understood. The aim of this review is to recognize the factors behind this intriguing phenomenon and analyse the consequences that it can bring in the management of the cardiovascular therapy in elderly patient. Finally, a new phenotype identified as “catabolic syndrome” has been postulated.